Cargando…
Targeting RGS4 Ablates Glioblastoma Proliferation
Glioblastoma (GBM) is the most common type of adult primary brain tumor with a median survival rate of less than 15 months, regardless of the current standard of care. Cellular heterogeneity, self-renewal ability and tumorigenic glioma cancer stem cell (GSC) populations contribute to the difficulty...
Autores principales: | Guda, Maheedhara R., Velpula, Kiran K., Asuthkar, Swapna, Cain, Charlie P., Tsung, Andrew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247588/ https://www.ncbi.nlm.nih.gov/pubmed/32392739 http://dx.doi.org/10.3390/ijms21093300 |
Ejemplares similares
-
GLUT1 and TUBB4 in Glioblastoma Could be Efficacious Targets
por: Guda, Maheedhara R., et al.
Publicado: (2019) -
Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism
por: Guda, Maheedhara R., et al.
Publicado: (2022) -
Immunopathology of galectin-3: an increasingly promising target in COVID-19
por: Caniglia, John L., et al.
Publicado: (2020) -
Metabolic targeting of EGFRvIII/PDK1 axis in temozolomide resistant glioblastoma
por: Velpula, Kiran K., et al.
Publicado: (2017) -
A potential role for Galectin-3 inhibitors in the treatment of COVID-19
por: Caniglia, John L., et al.
Publicado: (2020)